Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
addressed during public health emergencies
|
| gptkbp:advocacy |
required for administration
|
| gptkbp:approves |
gptkb:2001
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:associated_with |
bioterrorism threats
reduction in anthrax cases |
| gptkbp:availability |
limited to certain countries
|
| gptkbp:available_on |
pre-filled syringes
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
Phase III trials conducted |
| gptkbp:clinical_use |
post-exposure prophylaxis
pre-exposure prophylaxis used in outbreak situations |
| gptkbp:contains |
inactivated Bacillus anthracis spores
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
severe allergic reaction to components |
| gptkbp:developed_by |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:dosage_form |
3 doses
every 6 to 12 months for high-risk individuals |
| gptkbp:educational_resources |
available from health organizations
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:funding |
supported by government grants
|
| gptkbp:historical_significance |
first vaccine approved for anthrax prevention
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bio Thrax
|
| gptkbp:indication |
gptkb:military_personnel
laboratory workers handling anthrax first responders in anthrax outbreaks |
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
high in clinical studies
|
| gptkbp:is_recommended_by |
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization |
| gptkbp:is_recommended_for |
gptkb:military_personnel
laboratory workers handling anthrax |
| gptkbp:is_vulnerable_to |
inactivated vaccine
continues to evolve. subunit vaccine initial series followed by boosters 0, 7, and 21 or 28 days coordinated with public health agencies developed in response to bioterrorism threats. focus on improving stability and efficacy high efficacy in preventing anthrax disease inspired by historical anthrax outbreaks |
| gptkbp:manufacturer |
gptkb:Emergent_Bio_Solutions,_Inc.
gptkb:United_States |
| gptkbp:marketed_as |
gptkb:United_States
trade name Bio Thrax |
| gptkbp:packaging |
single-dose vials
|
| gptkbp:part_of |
anthrax vaccination program
|
| gptkbp:post_exposure_prophylaxis |
recommended after exposure to anthrax spores
|
| gptkbp:price |
varies by provider
|
| gptkbp:provides_guidance_on |
provided by CDC
provided by WHO established for administration and use |
| gptkbp:public_awareness |
increased after bioterrorism events
conducted to educate about anthrax risks |
| gptkbp:public_health_importance |
high due to anthrax risk
critical for bioterrorism preparedness |
| gptkbp:recommissioned |
with sterile water
|
| gptkbp:research |
ongoing for new formulations
ongoing for combination vaccines |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well-tolerated
|
| gptkbp:safety_measures |
ongoing post-marketing surveillance
|
| gptkbp:shelf_life |
up to 24 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever injection site reactions pain at injection site muscle aches rarely causes severe allergic reactions |
| gptkbp:stockpiled_by |
gptkb:U._S._government
|
| gptkbp:suitable_for |
pregnant women without consultation
individuals with certain immune disorders individuals with certain autoimmune disorders pregnant women unless absolutely necessary |
| gptkbp:supply_chain |
managed by government agencies for emergency use
|
| gptkbp:target_audience |
adults at high risk of anthrax exposure
|
| gptkbp:targets |
gptkb:disease
|
| gptkbp:trade_name_of |
gptkb:Anthrax_Vaccine_Adsorbed
|
| gptkbp:type_of_insurance |
may vary by plan
|
| gptkbp:used_for |
prevention of anthrax
|
| gptkbp:used_in |
biodefense programs
|
| gptkbp:bfsParent |
gptkb:Anthrax_Vaccine_Adsorbed_(AVA)
gptkb:Anthrax_vaccine gptkb:anthrax_vaccine |
| gptkbp:bfsLayer |
5
|